TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Virtual QA and management of outsourced activities

Virtual QA and management of outsourced activities

Virtual QA and Compliance Support for the Set Up and Management of Outsourced Activities

It is not surprising that the attraction towards the use of Outsourced Activities for Contract Manufacturing and associated services in the pharmaceutical industry remains strong once some of the benefits are understood.  The decision to engage with Contract Manufacturer’s is getting easier over time due to the continued evolution and development of sophisticated technologies and increased industry knowledge base. Outsourcing also provides a mechanism for increasing efficiency and productivity while reducing cost, and, is therefore of interest to pharmaceutical companies.

Selection of an outsourced supplier is not just about evaluation of their capabilities, expertise, cost and satisfactory timelines. What is equally important but often overlooked, is the evaluation of the proposed supplier’s business strategy, core competencies and company culture. Any element of outsourced work is an extension of your company’s business, and as such, working with a partner who holds similar values is more important than you might realize in terms of long-term success.

But how can you demonstrate adequate compliance oversight for activities that are outsourced? This can be a challenging and daunting task especially with the increased globalization and accompanying complexity of the pharmaceutical supply chains. Specifically, for virtual organisations, a robust and effective Quality Management System and Supplier Management programme is critical, as well as monitoring its ongoing effectiveness and suitability through periodic GxP Audit and Quality Management review.

As part of the initial supplier evaluation process, you should be seeking answers from both the supplier and within your own company, as applicable, to the following questions:

  • Does the existing Quality Management System (QMS) in your current company support adequate control and oversight of the outsourced activity?
  • Do you have a process in place to ensure timely, accurate and comprehensive oversight on the contracted activities? If not, what would this look like?
  • Are there adequate resources in place in your company with appropriate technical expertise to effectively analyze and understand technical issues that are incurred at the site of the CMO as they arise?
  • Does the procurement team within your company understand the compliance checks that are required to be in place as part of the supplier onboarding process?
  • Are there efficient lines of communication in place between compliance and procurement within your company and between the company and the supplier?
  • Do you have a supplier performance monitoring programme in place and will the supplier agree to support and participate in this?
  • Are the terms of the quality agreement achievable and acceptable to both parties?
  • Does the supplier have an appropriate change management process in place that facilitates customer approval on all applicable changes?
  • Will the supplier inform and involve the company upfront if a significant quality issue arises and how can this be ensured?
  • Is the suppliers understanding of a critical issue the same as the company’s? Are definitions of Critical, Major and Minor aligned?
  • Does the supplier have a process in place to ensure the keep abreast of industry changes, local and global compliance requirements?

 

The regulatory expectations around Outsourced Activities are made quite clear in various sections throughout Eudralex Volume 4. The full chapter on Outsourced Activities is contained at the following link: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/vol4-chap7_2012-06_en.pdf

PharmaLex has considerable experience in both the set up and operational support of quality and compliance services for different organisations which range from supporting a single element of the Quality System through to the outsourcing of the entire external Quality oversight of Manufacturing and Supply Chain activities. The ranges of services that PharmaLex support include, but are not limited to:

  • Workshops to understand and identify compliance and regulatory requirements as a result of changing business models in the pharmaceutical supply chain
  • Development of Quality Management Systems to support Wholesale Distribution Authorisation (WDA) and Marketing Authorisation Holder (MAH) activities
  • Set up and implementation of CMO Onboarding processes
  • Development of Quality Technical Agreements to support different business models
  • Development of Supply Chain Maps to reflect physical and financial product flows
  • Complaints, Recall and Product Quality Defects Management
  • Staff augmentation (Qualified Person, Responsible Person, Quality Assurance Subject Matter Experts and Quality Assurance Operational staff)
  • Vendor Management
  • GxP Audits and Mock Inspections

Whether you are seeking the set up of virtual quality and compliance activities or are seeking to outsource the quality and compliance element(s) of your business our experienced experts are here for you. PharmaLex have built up a wealth of expertise over the years and have a proven record of the ability to deliver in line with their company tagline “Confidence beyond Compliance”. Why not get in touch to find out more on the range of services that we offer by connecting with us on +353 1 846 4742 or email us at contactirl@pharmalex.com.

 

Related posts
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Points de vigilance vis-à-vis de la communication institutionnelle en France
Points de vigilance vis-à-vis de la communication institutionnelle en France
23rd November 2021
Search
Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
12 May

Patrick Nieuwenhuizen talks to BioPharm International about the Limitations of Sterility Testing and understanding the challenges and solutions of Aseptic Processing.

Read more: https://lnkd.in/d8cq4V6u

#sterilitytesting #asepticprocessing #pharma

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • During the bid defense we felt that you worked well as team and are very dynamic. Preparation of such a complex dossier really needs to be done in such a way.

    Large Pharma, Germany
    VP Regulatory Affairs
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for